摘要
人呼吸道合胞病毒(human respiratory syncytial virus,RSV)是引起婴幼儿下呼吸道感染的最重要的病毒病原,RSV载体疫苗可在人细胞内从头合成,形成的蛋白质构象与RSV自然感染后表达的完全相同,不会导致抗原表位的丧失或变化,形成的免疫力更利于抵抗随后的自然感染;经黏膜途径免疫不会产生疾病增强作用,且能突破母传抗体的干扰,因而受到广泛关注。对近年来RSV载体疫苗的研究进展进行了综述。
Human respiratory syncytial virus（RSV） is the leading viral agent of serious respiratory disease in infants and young children worldwide,infecting nearly all children one or more times by age 2.An intranasal live vector-based RSV vaccine mimics natural infection and presumably synthetized proteins in conformation similar these synthetized by natural infection.An intranasal live vector-based RSV vaccine is able to escape the immunosuppressive effects of maternal serum antibodies and avoid the immune-mediated enhanced disease.The advances in the live vector-based RSV vaccine is reviewed.
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2012年第1期92-96,共5页
China Biotechnology
基金
国家自然科学基金(30972604)
北京市自然科学基金(7092053)
中国博士后科学基金(20100470196)资助项目
关键词
呼吸道合胞病毒
载体疫苗
Respiratory syncytial virus Vector-based vaccine
